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Background: African Americans (AAs) are disproportionately affected by acute heart failure (AHF)
compared with other racial/ethnic groups. Disparities in AHF risk factors among AAs are attributed to
higher rates of hypertension and diabetes mellitus, lower socioeconomic status, higher dietary caloric
and salt intake, and biologic/genetic differences. However, AAs are frequently underrepresented in
AHF clinical trials, and race-related differences in risks and clinical outcomes are not well understood.
Objective: The aim of this work was to review published data on AHF in the AA population, including
management strategies that may differ based on race and common barriers to optimal care.
Methods: Publications were identified in Pubmed (through June 10, 2013) with the use of the search
strategy terms (acute heart failure) AND (black OR African American OR racial).
Results: Racial disparities in the quality of AHF care are relatively uncommon; however, racial differ-
ences in pathophysiology have resulted in differing pharmacologic recommendations (eg, isosorbide dini-
trate plus hydralazine is indicated only in AAs). Various socioeconomic factors influence disease
progression, treatment compliance, and hospitalization/rehospitalization rates.
Conclusions: Further research would enhance understanding of pathophysiologic heart failure differences
between racial groups. Programs are needed that incorporate known clinical and cultural differences to
improve quality of care and reduce the disease burden of AHF for all patients. (J Cardiac Fail
2014;20:533e540)
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States living with heart failure (HF), and as the American
population ages the prevalence of HF is expected to in-
crease such that O8 million people will be affected by
2030.1 Patients with HF are at significant risk for decom-
pensation, and acute heart failure (AHF) is the leading
cause of hospitalization in patients O65 years of age.2e4
It is estimated that O1 million patients are hospitalized
for AHF each year, accounting for O6.5 million days of
inpatient care.2,5 These hospitalizations account for w80%
of the estimated $20.9 billion in annual medical costs asso-
ciated with HF.1 In addition, hospitalization due to AHFY at Stony Brook School of Medicine, Stony Brook, New
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533signals a change in the progression of HF and worsened
prognosis, with 60- to 90-day postdischarge mortality rates
ofw9% and rehospitalization rates ofw30%.6 Thus, AHF
has emerged as a major public health issue, and strategies
are needed to prevent HF and improve the quality and effi-
ciency of care.1,2
Significant differences exist in the incidence rates of HF
based on race/ethnicity, with the highest rates reported for
African Americans.7 For example, the Multi-Ethnic Study
of Atherosclerosis (MESA) found that African Americans
were at significantly higher risk of developing HF compared
with European Americans (whites; hazard ratio, 1.81; 95%
confidence interval, 1.07e3.07).7 African Americans were
also the group with the highest proportion of incident HF
that was not associated with earlier myocardial infarction.7
Furthermore, the Health Aging, Body, and Composition
study showed that African American participants not only
were among those most likely to develop HF, but also had
higher rates of HF attributable to modifiable risk factors and
higher rehospitalization rates relative to white participants.8
These racial disparities in HF risk factors have been
attributed to a number of demographic and clinical dif-
ferences between African Americans and other groups,
including higher rates of hypertension and diabetes mel-
litus, lower socioeconomic status, higher dietary caloric
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the relative importance of these race-related differences
is not well understood, and there is a paucity of literature
specifically focused on the clinical characteristics of AHF
in the African American population. African Americans
have typically been underrepresented in many HF trials,
and large-scale high-quality studies are needed to better un-
derstand the influence of race on risk factors and clinical
outcomes associated with AHF.1,9
The purpose of the present work was to provide a review
of published data on AHF in the African American popula-
tion, including both acute and postdischarge care and bar-
riers associated with suboptimal outcomes.
Methods
Relevant publications were identified in Pubmed (through June
10, 2013) with the use of the search strategy terms (acute heart
failure) AND (black OR African American OR racial). This search
strategy yielded a total of 207 articles. A review of the abstracts
of these articles found 9 that were of definite interest concerning
the topic of presentation and/or management of AHF in African
Americans. The additional articles included in this review were
chosen by manual review of the bibliographies of selected articles.Results
Presentation of AHF
The clinical profile of AHF differs based on race/
ethnicity. Compared with other groups, African Americans
present with a mix of favorable and unfavorable prognostic
features.10 For example, evaluations of racial differences in
the baseline characteristics of patients admitted for AHF
from both the Outcomes of a Prospective Trial of Intrave-
nous Milrinone for Exacerbations of Chronic Heart Failure
(OPTIME-CHF) study and the 2001e2004 Acute Decom-
pensated Heart Failure National Registry (ADHERE) found
that compared with whites, African Americans were signifi-
cantly younger (mean ageO10 years younger) at presentation
and were more likely to have nonischemic cardiomyopathy;
both of these characteristics are associated with a more
favorable prognosis.10,11 In addition, African Americans
had lower inpatient and 60-day mortality rates.10,11
However, many studies have found that hypertension
is more common in African Americans compared with
whites with AHF, including OPTIME-CHF (79% vs 63%;
P ! .001),10 ADHERE (59% vs 47% with systolic blood
pressure O140 mm Hg; P ! .001),11 and the 2005e2008
American Heart Association’s Get With the Guidelinese
HF Program (83% vs 71% of patients hospitalized for
HF; P ! .001).12 Analyses of patient characteristics from
the 2003e2004 Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients With Heart Failure
(OPTIMIZE-HF) registry also showed that hypertension
is less well controlled in African Americans than in whites
hospitalized for acute HF. In that study, w36% of African
Americans had systolic blood pressure values O161 mmHg compared with 25% of the overall study population.13
In addition, salt sensitivity is very common among African
Americans,14 and salt sensitivity is associated with greater
blood pressure increases in African Americans compared
with whites.15
Findings of poorly controlled blood pressure occur
despite the fact that the majority of African American pa-
tients are on an antihypertensive treatment regimen when
AHF is diagnosed10,11,16 (eg, in the OPTIME-CHF trial,
75% of African Americans were receiving angiotensin-
converting enzyme inhibitor therapy compared with 68% of
whites).10 This suggests that antihypertensive dosing may be
too low and/or that recommended multidrug regimens are
not being prescribed for many African American patients.14
In addition to a higher prevalence of hypertension,
several studies have found that African Americans with
AHF have higher rates of diabetes,11,12,17 obesity,10e12
and renal insufficiency (eg, increased serum creatinine,
reduced glomerular filtration rate)11,12 than their white
counterparts. Several studies have also shown that at the
time of AHF diagnosis, African Americans have signifi-
cantly lower ejection fractions than whites10e12,17; eg, in
the ADHERE registry, 58% of African Americans had
left ventricular ejection fraction !40% or moderate to se-
vere impairment versus 50% of whites (P ! .001).11
Furthermore, analyses from the American Heart Associa-
tion’s Get With the GuidelineseHF Program showed that
compared with whites, black patients had significantly
higher levels of B-type natriuretic peptide at hospital
admission (1,604 vs 1,225 pg/mL; P ! .001), which is a
prognostic marker for AHF.12 These cardiovascular and
renal complications are indicators of more advanced dis-
ease in African Americans, despite similar or lower mortal-
ity rates compared with whites.11,12 Based on the observed
high rates of hypertension, renal insufficiency, obesity, and
diabetes among relatively young individuals, early inter-
vention strategies (eg, exercise, diet) are particularly impor-
tant among African Americans, given their increased
propensity to develop HF related to modifiable risk factors
and their high rates of rehospitalization compared with
white patients.8,11,12,14Management: Aspects of Acute Care
Consistent with the general population of patients with
AHF, most African American patients who are hospitalized
for AHF present with significant fluid overload. Aggressive
therapy with intravenous loop diuretics is regarded as stan-
dard first-line therapy for managing congested patients with
AHF.3,18 To reduce morbidity, therapy should be initiated as
early as possible in the emergency department, and it is crit-
ical that dosing be instituted in a manner that achieves relief
of congestion symptoms without inducing an excessively
rapid reduction in intravascular volume.3,18 Therefore,
monitoring of patients receiving intravenous loop diuretics
should include daily evaluation of volume status, systemic
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perfusion, weight, supine and standing vital signs, fluid
input and output, electrolyte levels, and renal function.18
Although several studies have shown that there are no
racial disparities in the overall approach or quality of inpa-
tient care for AHF,11,12,19,20 African Americans are more
likely to receive emergency department care compared
with whites. For example, in an analysis of emergency
department visits for AHF derived from the American
National Hospital Ambulatory Medical Care Survey from
1992 to 2001, African Americans had a 53% higher emer-
gency department visit rate relative to whites (14.2 vs 9.3
visits for AHF per 1,000 population).21 Although emer-
gency department care has been associated with better
long-term outcomes compared with inpatient hospitaliza-
tion, AHF patients place substantial burdens on emergency
departments at hospitals across the United States.21,22
Of more concern is the observation that in a retrospective
chart review of patients hospitalized for AHF at a Veterans
Administration Medical Center (n5 753), African American
patients delayed seeking treatment for AHF symptoms for
significantly longer periods compared with whites, Asians,
and Hispanics (mean 3.2 days vs 2.8, 2.9, and 2.8 days,
respectively; P 5 .019).23 Compared with other groups,
African Americans also had significantly lower functional
status (mean 1.8 vs 1.2 for Asians, 1.3 for Hispanics, and
1.5 for whites; P 5 .001) and higher readmission rates.23
The authors speculated that lack of compliance with
follow-up appointments, prescribedmedications, and dietary
recommendations may have contributed to the higher read-
mission rates among African Americans, although this was
not assessed in the study. Additionally, an analysis of data
from the ADHERE registry (n 5 58,465) showed that Afri-
can Americans were significantly more likely to experience
delays from the time of emergency department admission
for AHF to the initiation of intravenous diuretic treatment.22
These delays in hospitalization and initiation of diuretics are
worrisome, because early treatment is associated with better
clinical outcomes (eg, shorter hospital stay, lower in-hospital
mortality).18,22 Therefore, initiatives to improve ‘‘door-to-
diuretic time’’ are of particular interest to improve patient
outcomes (eg, shorter emergency department and hospital
stays and reduced rehospitalization rates) and reduce costs.
Another exception to the similarity of acute care between
African-American and white patients stems from results of
the African-American Heart Failure Trial (A-HeFT).24 That
randomized trial assessed a fixed dose of the nitric oxide
donoreantioxidant combination of isosorbide dinitrate
plus hydralazine (or placebo) added to standard therapy
for HF in 1,050 African-American patients with New
York Heart Association functional class III or IV HF.24
The study was terminated early in light of a significantly
higher mortality rate in the placebo arm. Analyses of avail-
able data showed that the primary end point (composite
score of weighted values for death from any cause, first hos-
pitalization for HF, and change in quality of life) and its in-
dividual components significantly favored isosorbide
dinitrate plus hydralazine over placebo. Active treatmentwas associated with a 43% improvement in overall survival,
a 33% relative reduction in the rate of first hospitalization
for HF, and slight but significant improvements in blood
pressure and quality of life compared with placebo.24 Sub-
sequent analyses of data from the A-HeFT trial support the
efficacy of this regimen across patient subgroups based on
age, sex, ischemic or nonischemic HF etiology, and history
of hypertension, atrial fibrillation, diabetes mellitus, and
chronic renal insufficiency.25,26 However, beneficial treat-
ment effects were not observed for patients without a history
of hypertension, patients not receiving loop diuretics, and pa-
tients receiving calcium channel blockers.25 It is important to
note that all patients were already on recommended HF med-
ications at the start of the study (angiotensin-converting
enzyme inhibitors, beta-blockers, diuretics, etc).25 Results
of an extension to the A-HeFT trial support the longer-
term efficacy of isosorbide dinitrate and hydralazine in
African-American patients (mean duration of treatment,
2096 116 days; annualized mortality rate, 6%).27 In contrast,
retrospective analyses of results from the VasodilatoreHeart
Failure Trials (V-HeFT) showed that although African
American patients treated with isosorbide dinitrate and
hydralazine had significantly reduced mortality rates com-
pared with placebo treatment, mortality rates in white pa-
tients were not significantly different from placebo.28
Based on the results of these studies, the combination of
isosorbide dinitrate and hydralazine is specifically indicated
for the treatment of HF as an adjunct to standard therapy
in self-identified black patients to improve survival, prolong
time to hospitalization for HF, and improve patient-reported
functional status.29 Current HF guidelines recommend use
of this combination in African-American patients with per-
sistently symptomatic New York Heart Association func-
tional class III or IV HF with reduced ejection fraction.18
However, this combination is underutilized in clinical prac-
tice, being prescribed in!20% of this population.30 More-
over, it has been observed that patient adherence to this
regimen is generally poor because of frequent adverse reac-
tions, including headache, dizziness, and gastrointestinal
complaints, along with the large number of tablets patients
must take (eg, maintenance doses in the A-HeFT extension
averaged 3.7 6 1.8 tablets per day).18,27,31
Compared with whites, African Americans may also have
a greater vasodilation response to nitroglycerin,32 which is
recommended as an addition to diuretic therapy for relief
of dyspnea in patients hospitalized for AHF.18 This could
make African Americans more susceptible to nitroglycerin-
induced headache and hypotension. Nitroglycerin should
not be used in patients with symptomatic hypotension, and
patients should be monitored for tachyphylaxis.18
A possible explanation for the greater efficacy of the iso-
sorbide dinitrateehydralazine combination and nitroglyc-
erin in African Americans may be that nitric oxide levels
are reduced more and angiotensin II levels are increased
less in African Americans with HF compared with their
white counterparts.33 Genetic studies support this hypothe-
sis, showing that African Americans are more likely to have
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genes compared with other ethnic groups.34 Results of the
Genetic Risk Assessment of Heart Failure (GRAHF) sub-
study of the A-HeFT trial have also shown that aldosterone
synthase polymorphisms at position 344 are predictive
of HF outcomes.35 The 344C allele was associated with
higher aldosterone expression levels and poorer event-free
survival in African Americans with HF; however, the TT
genotype, which is common in African Americans and
linked to low-renin hypertension, was associated with
high levels of response to isosorbide dinitrateehydralazine
therapy.35 Another contributing factor may be related to
the observation that high levels of sodium consumption
by salt-sensitive individuals results in suppression of uri-
nary nitric oxide metabolites and increased angiotensin II
production.36,37Management: Aspects of Postdischarge Care
Discharge planning in the AHF population should be
relatively comprehensive and include a planned telephone
or clinic follow-up shortly after discharge and referral to
a cardiologist for long-term disease management. The over-
arching goal of discharge planning is to reduce the risk of
readmission, which is w25% within the first 30 days after
discharge.3,18 Important issues to address at hospital dis-
charge include identification and management of factors
that may exacerbate AHF, transitioning from intravenous
to oral medication, and provision of patient education ma-
terials to ensure patients understand how to take their medi-
cation, how to recognize signs of worsening HF, and the
importance of a healthy lifestyle.3,33,38
Aswith acute care, there appears to be little or no racial bias
regarding the prescribing of discharge medications, and many
studies have shown that African-American patients actually
have shorter intensive care unit and overall hospital stays, as
well as lower in-hospital mortality rates, compared with white
patients.10,11,39 In an examination of medication utilization
based on race in patients discharged from the hospital with a
principal diagnosis of HF, Harjai et al39 hypothesized that Af-
rican Americans would be less likely to receive medical ther-
apy compared with whites. Contrary to this hypothesis, the
authors found that African Americans (n 5 182) were more
likely than whites (n 5 384) to receive angiotensin-
converting enzyme inhibitors (adjusted odds ratio, 1.84;
95% confidence interval, 1.31e3.01), vasodilator therapy
(adjusted odds ratio, 1.97; 95% confidence interval,
1.20e3.23), and combination therapy (adjusted odds ratio,
1.66; 95% confidence interval, 1.02e2.69).39
Similarly, data from the ADHERE database (2001e2004)
and the OPTIME-CHF trial support the finding that pread-
mission and postdischarge oral therapy is generally similar
for all patients hospitalized for AHF, regardless of race.10,11
Small observed differences are consistent with the findings
of Harjai et al39 that angiotensin-converting enzyme in-
hibitor and angiotensin receptor blocker use is higher in
African Americans than in whites.10,11 In contrast, b-blockeruse has been observed to be slightly higher in white patients
compared with African Americans at the time of admission
and slightly lower at hospital discharge.10,11 It should be
noted, however, that most available data on postdischarge
medication use predates the A-HeFT trial,24 and trends
may have shifted with the specific indication of isosorbide
dinitrate plus hydralazine in African-American patients
with HF.
The finding that angiotensin-converting enzyme inhi-
bitors have often been used more frequently in African
Americans10,11,19,39 is somewhat surprising, given that
several studies indicate that African Americans may have
decreased responsiveness to these agents, and increased
risk of angioedema associated with angiotensin-converting
enzyme inhibitors, compared with general HF popula-
tions.14,18,33 However, the overall risk of angioedema is
low. In a randomized double-blind 24-week study, for
example, the incidence of angioedema among hypertensive
patients treated with 5e40 mg/d enalapril was 1.62%
(20/1,237) in African Americans compared with 0.55%
(61/11,126) in whites.40 Current HF guidelines stress that
although African Americans may not achieve the same
level of benefit from angiotensin-converting enzyme inhib-
itors, this class of drugs has been shown to significantly
reduce risks of renal disease and cardiovascular mortality,
particularly in patients with reduced left ventricular ejec-
tion fraction. Therefore, angiotensin-converting enzyme in-
hibitors (or angiotensin receptor blockers) are uniformly
recommended as an important component of the long-
term management of HF.3,18,31,33
Despite similarities between African Americans and
whites in acute care, discharge planning, and medication
utilization, in the outpatient setting African Americans
face significantly increased risks of readmission17,19,41
and functional decline.42 In a 2003 retrospective analysis
of possible racial differences in quality of care using data
from the National Heart Failure Project, Rathore et al19
found that among Medicare beneficiaries hospitalized for
HF in 1998 and 1999 (n 5 29, 732), African Americans
had significantly higher readmission rates within 1 year
of discharge compared with white patients (68.2% vs
63.0%, respectively; P! .001), despite having lower risks
of 30-day and 1-year mortality. The authors suggested that
differences in readmission rates may be related to differences
in adherence to pharmacotherapy and diet regimens,43 failure
to recognize the early symptoms of worsening HF, delays in
seeking care,23 generally lower functional status,44 and/or
poorer-quality follow-up care.19
In a more recent study, Joynt et al41 found that high re-
admission rates continue to be disproportionately problem-
atic for African Americans compared with whites. Those
authors evaluated 30-day readmission rates for Medicare
beneficiaries discharged after hospitalization for acute myo-
cardial infarction, HF, or pneumonia from 2006 to 2008
and found that among patients with HF (n 5 1,346,768), re-
admission rates were higher for African Americans than for
whites: 27.9% vs 27.1%, respectively (odds ratio, 1.04; 95%
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confidence interval, 1.03e1.06). These findings are again
suggestive of a lack of high-quality outpatient care in elderly
African-American populations.41
In a prospective cohort study of 82 African-American
and 316 white patients $50 years of age who were hospi-
talized with AHF, these 2 groups had similar age-adjusted
6-month mortality rates (19.5% vs 17.2%); however, African
Americans had a greater functional decline (37.6% vs
24.7%) and a nearly 50% increased risk of either death or
functional decline in activities of daily living (relative
risk, 1.45; 95% confidence interval, 1.06e1.81).42 These
differences could not be explained by clinical, socioeco-
nomic, access to care, or quality of life differences, but
may have been due to differences in the pathogenesis of
HF and response to treatment.42
Another significant difference in the care received by
African-American versus white patients with AHF is that
African Americans are less likely to have a cardiologist
as their primary attending physician. In an analysis of
data from the Study to Understand Prognoses and Prefer-
ences for Outcomes and Risks of Treatments (SUPPORT;
n 5 1,298), African Americans were significantly less likely
to receive care from a cardiologist (adjusted odds ratio, 0.53;
95% confidence interval, 0.35e0.80).45 Other factors associ-
ated with a decreased likelihood of being treated by a cardi-
ologist included annual income !$11,000, age O80 years,
and education !12 years. The study was not powered to
determine whether the observed differences were due to pa-
tient preferences for care or inequalities in the health care
system, but the results indicated that there was a correlation
between cardiologist care and socioeconomic status.45
Nonadherence to diet and/or medication has also been
documented as a major problem among African Americans
who experience decompensated HF. In a study that specif-
ically sought to elucidate precipitating factors for cardiac
decompensation and subsequent hospitalization in an
American urban minority population (n 5 101), in which
97% of the participants were African American, nonadher-
ence to prescribed medical regimens was the most promi-
nent issue, documented in nearly two-thirds of cases.43
Noncompliance with dietary recommendations was obser-
ved in 22% of patients, and 37% of patients failed to
comply with both dietary and pharmacologic recommenda-
tions.43 It is likely that a lack of ongoing outpatient educa-
tion and support contributes to poor medication and dietary
adherence.43 The authors of that study43 observed also that
emotional and environmental stresses were precipitating
factors for HF decompensation in w26% of patients.
Consistently with those findings, Sharma et al46 observed
that 45% of patients receiving care at inner-city hospitals
with high volumes of black patients (n 5 134; 86% African
American or Caribbean black) exhibited symptoms of de-
pression. Of patients with depressive symptoms, 60% had
functional impairment (eg, difficulty doing work, performing
activities at home, or getting along with other people),suggesting that depression may be a contributing factor to
poor adherence to treatment.46
As with lack of access to cardiologist care, socioeco-
nomic factors, including income, educational status, hous-
ing, and employment status, may affect the postdischarge
quality of care received by African Americans with AHF.33
Lower socioeconomic status among African Americans
may contribute to nonadherence to diet and medication rec-
ommendations, because poorer patients may have limited
access to health care resources and may be unable to afford
expensive medications or high-quality food needed to
maintain a healthy and low-sodium diet.43,44 Another
contributing factor may be that providers are not asking
whether their patients have issues related to medication
expense, and consequently, are not tailoring prescribing
patterns accordingly. In addition, transportation issues and
a lack of ongoing education and support for adhering to
prescribed medications may interfere with outpatient
follow-up.44,47 Awareness of these socioeconomic factors
is important when developing resources for improved HF
care. For example, researchers at the University of Chicago
Medical Center used a text message communication plat-
form designed to provide self-care reminders and patient
education materials to a largely African-American popula-
tion with AHF; however, 12 of 51 patients (24%) screened
for enrollment were not eligible, because they did not have
access to a personal cell phone.48 Thus, although eligible
participants in that program reported a high level of satis-
faction, along with decreased salt intake and fewer missed
pills, access to the required technology presented a signifi-
cant barrier for many individuals.48
Although many studies highlight the importance of socio-
economic factors in postdischarge care, racial differences in
health literacy are also important. The National Assessment
of Adult Literacy showed that 24% of African Americans,
compared with only 9% of whites, scored at the lowest level
(below basic).49 Chaudhry et al50 observed that racial differ-
ences in health literacy and access to care persist in recently
hospitalized patients with AHF even after adjustment for
education, income, and insurance status. Results of this
analysis of data from the Telemonitoring to Improve Heart
Failure Outcomes (Tele-HF) study showed that compared
with white patients (n 5 820), African-American patients
(n 5 644) were more likely to have poor health literacy
(24.4% vs 9.7% [odds ratio, 2.98; 95% confidence interval,
2.18e4.08]), absence of a provider primarily responsible
for their healthcare (23.6% vs 8.7% [odds ratio, 3.24; 95%
confidence interval, 2.34e4.50]), and limited access to med-
ical specialists (17.9% vs 11.7% [odds ratio, 1.65; 95% con-
fidence interval, 1.20e2.26]).50 African Americans were also
more likely to report cost as a deterrent to seeking health
care (25.0% vs 10.8% [odds ratio, 2.76; 95% confidence in-
terval, 2.03e3.75]) and to report that cost prohibited them
from taking their medication (25.3% vs 13.2% [odds ratio,
2.22; 95% confidence interval, 1.66e2.97]).50
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Although AHF health care disparities between different
racial/ethnic groups may have narrowed in recent years,
continued attention to social, educational, and economic
factors is necessary to reduce health care costs and disease
burden as the American population ages and minority pop-
ulations increase.51 For example, community revitalization
and education programs can markedly improve residents’
health status in areas where healthy and nutritious foods
are unavailable or too costly, where safety concerns limit
people’s willingness to exercise outdoors or let their chil-
dren play outside;-and where inexpensive processed foods
and high-calorie beverages are prevalent. Poor and minority
communities are also frequent targets of advertising cam-
paigns for tobacco, alcohol, and high-calorie/high-salt
foods.51 In addition, the Association of Black Cardiologists
reports that lack of health insurance, limited access to a
nearby health care provider, language and cultural barriers,
and low levels of health literacy are all significant obstacles
that may prevent minorities from receiving adequate health
care.52 However, the Association of Black Cardiologists is
working to eliminate racial disparities in cardiovascular
care through educational, research, and patient advocacy
programs. On the Association’s Web site, patients can
find useful information for managing HF, blood pressure,
diabetes, and lipids, as well as medication guides and tips
to promote healthy eating, physical activity, stress reduc-
tion, weight management, and smoking cessation.52
As evidenced by the available literature on AHF in
African American patients, it is important for health care
providers to gather more thorough information on individ-
ual patient and disease characteristics, such that barriers
and opportunities for improving outcomes can be identified
and addressed as an integral part of the disease manage-
ment plan. Treatment and education strategies should be
tailored to meet each individual’s needs. In this regard,
the importance of obtaining a thorough dietary history
cannot be overstated, particularly identification of excessive
sodium intake, given the known increase in salt sensitivity
among African Americans and its relationship with nitrate
response.3,14,15,37 Questions regarding socioeconomic and
cultural issues and barriers, including access to medication,
healthy food, transportation, and education, should be asked
on an ongoing basis and addressed as needed. Blood pressure
control is also a key issue in both acute and postdischarge
settings. When hospitalization for AHF is required, it should
be viewed as an opportunity to adjust medications to achieve
target blood pressure values and establish strategies to opti-
mize future long-term antihypertensive treatment regimens.3
To date, clinical trials have underrepresented the African-
American population.33 Accordingly, evidence-based prac-
tice guidelines for AHF management provide limited insight
into the nuances of managing these patients and associated
outcomes,3,18,33,53 with most currently available data derived
from the white population. For example, the recommenda-
tions for treatment of hospitalized patients included in the2013 American College of Cardiology Foundation/American
Heart Association guideline for the management of HF are
predominantly based on studies in which less than one-
fourth of the population was African American.18 This is
especially problematic considering that data from trials
such as A-HeFT suggest that there may be significant mech-
anistic differences driving the progression of HF in African
Americans compared with other populations (eg, nitrate sensi-
tivity).33 These differences may result in markedly different
responses to therapy among different racial/ethnic groups.
Furthermore, results from clinical trials that have underrepre-
sented the African-American population have not been consis-
tently reproduced in community health care settings.33
Because the focus of the Patient Protection and Afford-
able Care Act54 is on prevention of chronic diseases such
as HF, educating patients about the importance of a healthy
lifestyle and adherence to treatment, along with increasing
awareness about possible triggers for decompensation, is
more critical than ever. Individualized treatment strategies
should be used across all racial and ethnic groups, taking
into account physiologic markers, along with each patient’s
unique self-care challenges.
Although this analysis of the literature shows that few
racial disparities exist in current measures of quality of
care, the burden of AHF is still greatest in the African-
American population owing to a range of genetic, physio-
logic, and socioeconomic factors. Future research should
focus on enhancing the current understanding of pathophys-
iologic HF differences between African-American and white
populations. In addition, programs are needed to improve
quality of care and reduce disease burden for all patients
with AHF. To develop such programs, better understanding
is needed of the associations of socioeconomic status, access
to care, self-care attitudes, treatment compliance, and health
care literacy with risks for hospital admission/readmission.
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